LEH and UNIIQ close investment in Imuno Therapeutics

19 November 2021, LEH and UNIIQ invest a total 300,000 in seed capital for Imuno Therapeutics B.V., a new Leiden based immunotherapy technology business. Imuno will use the funds to broaden the range of cancer specific epitopes to lay the foundation for novel targeted therapies.